interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Rolapitant Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Rolapitant Hydrochloride, and who makes it?

Rolapitant Hydrochloride appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Rolapitant Hydrochloride2 dosage-form groups in the Orange Book
0generic makers listed
  1. Rolapitant Hydrochloride appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Emulsion, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

201520202025203001brand 2017data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Varubi. No generic is listed as marketed.

201520202025203001brand 2015data datePatent 8404702 listed to expire 4 April 2027Patent 7981905 listed to expire 4 April 2027Patent 7563801 listed to expire 4 April 2027Patent 8178550 listed to expire 4 April 2027Patent 7049320 listed to expire 19 August 2028Patent 8470842 listed to expire 18 January 2029Patent 8361500 listed to expire 9 October 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 4 April 2027Patent 8404702
  • 4 April 2027Patent 7981905
  • 4 April 2027Patent 7563801 drug product
  • 4 April 2027Patent 8178550 drug substance
  • 19 August 2028Patent 7049320 drug substance
  • 18 January 2029Patent 8470842
  • 9 October 2029Patent 8361500 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.